Product Description
Nifurtimox has been used to treat Chagas disease for 40 years, but tolerance and safety data in adults are scarce. Nifurtimox is poorly tolerated among adults with chronic Chagas disease, resulting in a low treatment completion rate. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/20932171/)
Mechanisms of Action: DNA Cleaver
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Argentina | Chile | Colombia | Mexico | Peru | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: Bayer
Company Location:
Company Founding Year: 1863
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Brain Stem Cancer|Breast Cancer|Central Nervous System Cancer|Glioma|Lung Cancer|Medulloblastoma|Melanoma|Neuroblastoma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
CTR20220156 |
CTR20220156 | P1 |
Recruiting |
Glioma|Lung Cancer|Medulloblastoma|Brain Stem Cancer|Melanoma|Breast Cancer|Central Nervous System Cancer |
None |
2025-04-29 |
Patient Enrollment |
|
CTR20190136 |
CTR20190136 | P1 |
Recruiting |
Neuroblastoma |
None |
2025-04-29 |
Patient Enrollment|Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
10/04/2023 |
News Article |
Chagas Disease Market Size, Trends, Industry Statistics and Latest Insights Till 2033 |
|
06/14/2022 |
News Article |
BioNJ Honors NJ's Innovators & the Patients Who Inspire Them |
|
05/05/2021 |
News Article |
The global rare diseases market was valued at US$xx billion in 2021 |
|
08/07/2020 |
News Article |
U.S. Food and Drug Administration Approves Lampit® (nifurtimox) for the Treatment of Chagas Disease in Children |